SPET–CT in thyroid cancer: a systematic review

被引：2
作者：
Wong K.K. [1 ,2 ,3 ]
Wale D.J. [1 ]
Fig L.M. [2 ]
Gross M.D. [1 ,2 ]
机构：
[1] Division of Nuclear Medicine, Department of Radiology, University of Michigan Hospital, Ann Arbor, 48109, MI
[2] Department of Veterans Affairs Health System, Nuclear Medicine Service, Ann Arbor, 48105, MI
[3] Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, B1G505 University Hospital SPC 5028, 1500 E. Medical Center Drive, Ann Arbor, 48109-5028, MI
来源：
Clinical and Translational Imaging | 2014年 / 2卷 / 6期
关键词：
Medullary thyroid cancer; Radioiodine; SPECT/CT; SPECT–CT; Well-differentiated thyroid cancer;
D O I：
10.1007/s40336-014-0085-8
中图分类号：
学科分类号：
摘要：
The purpose of this study was to systematically review the utility of single-photon emission tomography–computed tomography (SPET–CT) fusion imaging in the investigation of thyroid cancer. We performed a systematic search of the world literature on radionuclide SPET–CT imaging of thyroid cancer using the medical databases Medline (OVID) and PubMed. The following search terms were used to identify relevant studies: (a) thyroid, combined with (b) SPECT/CT or SPECT–CT or SPET/CT or SPET–CT. The electronic searches returned citations for 1,189 potentially eligible articles and 98 abstracts were reviewed for relevance by two co-authors. Thirty-one peer-reviewed full articles reporting the utility, value and diagnostic performance of radioiodine SPET–CT for the imaging of well-differentiated thyroid cancer were selected. The quality of these studies was assessed using the quality assessment of diagnostic accuracy studies-2 tool. As there was heterogeneity in the studies, a systematic review analysis was conducted as our chosen research synthesis method. A total of 31 studies published between 2003 and 2014 report the utility of radioiodine SPET–CT. These studies uniformly found incremental diagnostic value of I-123 and I-131 SPET–CT over SPET and/or planar imaging. SPET–CT allows accurate characterization of radioiodine uptake in the neck and at distant sites, clarifies equivocal foci of radioactivity, improves specificity for disease, and evaluates benign physiological etiologies. Additional pilot uses of SPET–CT have been reported, e.g., for thyroid nodule evaluation, medullary thyroid cancer work-up, and investigation of lingual thyroid. Radioiodine SPET–CT fusion imaging of thyroid cancer has incremental utility, improving image interpretation as compared to planar and SPET imaging. It is likely to see more widespread application in the future. © 2014, Italian Association of Nuclear Medicine and Molecular Imaging.
引用
收藏
页码：459 / 475
页数：16
相关论文
共 101 条
[1]  
Chung J.K., Sodium iodide symporter: its role in nuclear medicine, J Nucl Med, 43, pp. 1188-1200, (2002)
[2]  
Dai G., Levy O., Carrasco N., Cloning and characterization of the thyroid iodide transporter, Nature, 379, pp. 458-460, (1996)
[3]  
Smanik P.A., Liu Q., Furminger T.L., Ryu K., Xing S., Mazzaferri E.L., Jhiang S.M., Cloning of the human sodium iodide symporter, Biochem Biophys Res Commun, 226, pp. 339-345, (1996)
[4]  
Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., McIver B., Pacini F., Schlumberger M., Sherman S.I., Steward D.L., Tuttle R.M., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 19, pp. 1167-1214, (2009)
[5]  
Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013, CA Cancer J Clin, 63, pp. 11-30, (2013)
[6]  
Davies L., Welch H.G., Increasing incidence of thyroid cancer in the United States, 1973–2002, JAMA, 295, pp. 2164-2167, (2006)
[7]  
Chen A.Y., Jemal A., Ward E.M., Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005, Cancer, 115, pp. 3801-3807, (2009)
[8]  
Hay I.D., McDougall I.R., Sisson J.C., A proposition for the use of radioiodine in WDTC Management, J Nucl Med, 50, pp. 328-329, (2009)
[9]  
Hay I.D., McConahey W.M., Goellner J.R., Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000, Trans Am Clin Climatol Assoc, 113, pp. 241-260, (2002)
[10]  
Jonklaas J., Sarlis N.J., Litofsky D., Ain K.B., Bigos S.T., Brierley J.D., Cooper D.S., Haugen B.R., Ladenson P.W., Magner J., Robbins J., Ross D.S., Skarulis M., Maxon H.R., Sherman S.I., Outcomes of patients with differentiated thyroid carcinoma following initial therapy, Thyroid, 16, pp. 1229-1242, (2006)
12345678910